Lapatinib Interactions
There are 640 drugs known to interact with lapatinib, along with 9 disease interactions, and 2 alcohol/food interactions. Of the total drug interactions, 123 are major, 502 are moderate, and 15 are minor.
- View all 640 medications that may interact with lapatinib
- View lapatinib alcohol/food interactions (2)
- View lapatinib disease interactions (9)
Most frequently checked interactions
View interaction reports for lapatinib and the medicines listed below.
- Abraxane (paclitaxel protein-bound)
- Abraxane (paclitaxel protein-bound)
- Adriamycin (doxorubicin)
- Adriamycin (doxorubicin)
- L-Arginine (arginine)
- L-Arginine (arginine)
- L-Carnitine (levocarnitine)
- L-Carnitine (levocarnitine)
- L-Cysteine (cysteine)
- L-Cysteine (cysteine)
- Lithium Carbonate ER (lithium)
- Lithium Carbonate ER (lithium)
- Metoprolol Succinate ER (metoprolol)
- Metoprolol Succinate ER (metoprolol)
- Paracetamol (acetaminophen)
- Paracetamol (acetaminophen)
- Valproate Sodium (valproic acid)
- Valproate Sodium (valproic acid)
- Vitamin B1 (thiamine)
- Vitamin B1 (thiamine)
- Vitamin B12 (cyanocobalamin)
- Vitamin B12 (cyanocobalamin)
- Vitamin B6 (pyridoxine)
- Vitamin B6 (pyridoxine)
- Vitamin D3 (cholecalciferol)
- Vitamin D3 (cholecalciferol)
- Vitamin K (phytonadione)
- Vitamin K (phytonadione)
- Vitamin K2 (menaquinone)
- Vitamin K2 (menaquinone)
Lapatinib alcohol/food interactions
There are 2 alcohol/food interactions with lapatinib.
Lapatinib disease interactions
There are 9 disease interactions with lapatinib which include:
- cardiomyopathy
- dermatologic toxicities
- pulmonary toxicity
- QT prolongation
- pulmonary toxicity
- liver dysfunction
- CHF
- thrombocytopenia
- renal impairment
Report options
More about lapatinib
- lapatinib consumer information
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: EGFR inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Ibrance
Ibrance is used to treat HR-positive, HER2-negative breast cancer in postmenopausal women or men ...
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
